These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37773048)

  • 1. Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.
    Parra-Rodriguez L; O'Halloran J; Wang Y; Jin W; Dastgheyb RM; Spence AB; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Maki PM; Xu Y; Rubin LH
    AIDS; 2024 Feb; 38(2):167-176. PubMed ID: 37773048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
    Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
    Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.
    Williams DW; Li Y; Dastgheyb R; Fitzgerald KC; Maki PM; Spence AB; Gustafson DR; Milam J; Sharma A; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Weber KM; Xu Y; Rubin LH
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):181-194. PubMed ID: 31933016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
    Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T
    Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
    Perry CM
    Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Greig SL; Deeks ED
    Drugs; 2016 Jun; 76(9):957-68. PubMed ID: 27189707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    Sun L; He Y; Xu L; Zhao F; Zhou Y; Zhang L; Peng Q; Zhang H; Zhang Q; Cao T; Song Y; Wang S; Rao M; Jia X; Liu X; Zhou J; Ju B; Wang H; Liu J
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S8-S15. PubMed ID: 36094509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
    Mills A; Arribas JR; Andrade-Villanueva J; DiPerri G; Van Lunzen J; Koenig E; Elion R; Cavassini M; Madruga JV; Brunetta J; Shamblaw D; DeJesus E; Orkin C; Wohl DA; Brar I; Stephens JL; Girard PM; Huhn G; Plummer A; Liu YP; Cheng AK; McCallister S;
    Lancet Infect Dis; 2016 Jan; 16(1):43-52. PubMed ID: 26538525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.